Emergent BioSolutions (EBS) Research & Development (2011 - 2026)
Emergent BioSolutions (EBS) posted quarterly Research & Development of $10.5 million for Q1 2026, down 30.46% year-over-year from $15.1 million in Q1 2025, and down 13.22% quarter-over-quarter from $12.1 million in Q4 2025.
Emergent BioSolutions (EBS) Research & Development (2011 - 2026) Analysis & Trends
Emergent BioSolutions' Research & Development history runs 16 years deep, the most recent figure standing at $10.5 million for Q1 2026.
- In Q1 2026, Research & Development fell 30.46% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $48.6 million (down 31.26% YoY), while the FY2025 annual figure was $53.2 million, down 24.75% from the prior year.
- Research & Development for Q1 2026 stood at $10.5 million, down from $12.1 million in the prior quarter.
- The five-year high for Research & Development was $49.8 million in Q2 2022, with the low at $9.1 million in Q4 2024.
- The 5-year median for Research & Development is $15.3 million (2023), against an average of $25.4 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development sank 69.05% in 2024, then soared 32.97% in 2025.
- Emergent BioSolutions' Research & Development stood at $47.0 million in 2022, then sank by 37.45% to $29.4 million in 2023, then tumbled by 69.05% to $9.1 million in 2024, then jumped by 32.97% to $12.1 million in 2025, then retreated by 13.22% to $10.5 million in 2026.
- Business Quant data shows EBS's Research & Development at $10.5 million in Q1 2026, $12.1 million in Q4 2025, and $13.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 9.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.20 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | 12.10 Mn |
| Sep 30, 2025 | 13.50 Mn |
| Jun 30, 2025 | 12.50 Mn |
| Mar 31, 2025 | 15.10 Mn |
| Dec 31, 2024 | 9.10 Mn |
| Sep 30, 2024 | 13.80 Mn |
| Jun 30, 2024 | 32.70 Mn |
| Mar 31, 2024 | 15.10 Mn |
| Dec 31, 2023 | 29.40 Mn |
| Sep 30, 2023 | 15.30 Mn |
| Jun 30, 2023 | 26.00 Mn |
| Mar 31, 2023 | 40.70 Mn |
| Dec 31, 2022 | 47.00 Mn |
| Sep 30, 2022 | 42.20 Mn |
| Jun 30, 2022 | 49.80 Mn |
| Mar 31, 2022 | 46.40 Mn |
| Dec 31, 2021 | 38.20 Mn |
| Sep 30, 2021 | 49.60 Mn |